Immune Response News and Research

RSS

Microbiome 'profiling' may help identify people at risk of long COVID

The make-up of the gut microbiome may be linked to a person's risk of developing 'long COVID' many months after initial infection with SARS-CoV-2, the virus responsible for COVID-19 infection, suggests research published online in the journal Gut.

26 Jan 2022

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

A new study assesses SARS-CoV-2 antigen-specific cytokine responses in a cohort of SARS-CoV-2 infected individuals with varying levels of disease.

26 Jan 2022

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

In adults who had previously received a full regimen of any of three COVID-19 vaccines granted Emergency Use Authorization (EUA) or approved by the U.S. Food and Drug Administration, an additional booster dose of any of these vaccines was safe and prompted an immune response, according to preliminary clinical trial results reported in The New England Journal of Medicine.

26 Jan 2022

CDC tells pharmacies to give 4th covid shots to immunocompromised patients

The Centers for Disease Control and Prevention reached out to pharmacists Wednesday to reinforce the message that people with moderate to severe immune suppression are eligible for fourth covid shots.

26 Jan 2022

Antibodies against SARS-CoV-2 found to persist for up to 15 months after infection

In a new study, a team of researchers explored the association between total immunoglobulin (IgM, IgA, and IgG) against SARS-CoV-2 and protective immunity.

26 Jan 2022

Anti-SARS-CoV-2 antibodies found in wild mustelids in France

A new study focused on the identification of SARS-CoV-2 infection in wild mustelids in the French region of Brittany.

26 Jan 2022

Understanding immune responses to SARS-CoV-2 infections in children

A study published in the journal Immunity analyzed the varied manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children.

26 Jan 2022

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

In a recent study posted to the bioRxiv* preprint server, researchers evaluated the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated inflammatory marker interferon (IFN) repression in hosts.

25 Jan 2022

Spike-mediated CFTR inhibition accounts for airway inflammation in COVID-19

A new study looks at the molecular level inhibition of the protective CFTR gene by the SARS-CoV-2 spike protein.

25 Jan 2022

Pharmacies are turning away immunocompromised patients seeking 4th covid shot

Patients with weakened immune systems — who are at high risk from covid-19 — say pharmacies are turning them away when they seek additional vaccine doses recommended by federal health officials.

25 Jan 2022

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

A new preprint available on medRxiv* demonstrates the marked improvement in the immune response when the mRNA vaccine BNT162b2, from Pfizer/BioNTech, is used for the third dose after a primary two-dose series of an inactivated whole virus vaccine.

25 Jan 2022

Current vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2 variants

Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2.

24 Jan 2022

The long-term neurologic consequences of COVID-19

A team of researchers recently provided insights into central nervous system consequences of the coronavirus disease 2019 (COVID-19) in a perspective paper published in the Science journal.

24 Jan 2022

Blood proteins could be potential targets for future drugs to slow aging process

Two blood proteins have been shown by scientists to influence how long and healthy a life we live, research suggests.

24 Jan 2022

Study explains why Omicron infections are less likely to cause severe disease

A new study by researchers from the University of Kent and the Goethe University Frankfurt shows that the SARS-CoV-2 Omicron variant is less effective than Delta at blocking a cellular defense mechanism against viruses, the so-called “interferon response”.

24 Jan 2022

Attenuated tissue immune responses against SARS-CoV-2 in obese and non-obese patients

In a new study, researchers evaluated the single-cell transcriptomes from bronchiolar lavage in three adult cohorts comprising of obese and non-obese SARS-CoV-2 patients.

24 Jan 2022

Antibody response 18 months after SARS-CoV-2 infection in vaccinated and unvaccinated individuals

A new study assessed the dynamics of IgG titers over 18 months in patients who had recovered from COVID-19 infections during March 2020.

24 Jan 2022

Research shows depletion of extracellular vesicles weakens immune response towards SARS-CoV-2

Over the past several years, considerable effort has been made towards developing better diagnostic and prognostic tools. However, until now, the focus of research has mainly been on the virus itself or the immune response it triggers. To unify diagnostic and prognostic tools for COVID-19 analyses, researchers propose using extracellular vesicles (EVs) from serum liquid biopsies.

24 Jan 2022

Researchers are in the race to beat Omicron

David Veesler and his lab members aren't getting much sleep these days. In the final weeks of 2021, he and his team worked around the clock to post four coronavirus papers on the preprint server bioRxiv.

24 Jan 2022

Study shows how SARS-CoV-2 Omicron evades our immune response and remains infective

A recent study published in the journal Science brings a detailed chemical and molecular perspective on the improved evasion of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the retention of strong interactions with the receptor as two principal factors underneath the notorious transmissibility of the SARS-CoV-2 Omicron variant.

23 Jan 2022

Immune Response News and Research

Microbiome 'profiling' may help identify people at risk of long COVID

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

CDC tells pharmacies to give 4th covid shots to immunocompromised patients

Antibodies against SARS-CoV-2 found to persist for up to 15 months after infection

Anti-SARS-CoV-2 antibodies found in wild mustelids in France

Understanding immune responses to SARS-CoV-2 infections in children

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

Spike-mediated CFTR inhibition accounts for airway inflammation in COVID-19

Pharmacies are turning away immunocompromised patients seeking 4th covid shot

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

Current vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2 variants

The long-term neurologic consequences of COVID-19

Blood proteins could be potential targets for future drugs to slow aging process

Study explains why Omicron infections are less likely to cause severe disease

Attenuated tissue immune responses against SARS-CoV-2 in obese and non-obese patients

Antibody response 18 months after SARS-CoV-2 infection in vaccinated and unvaccinated individuals

Research shows depletion of extracellular vesicles weakens immune response towards SARS-CoV-2

Researchers are in the race to beat Omicron

Study shows how SARS-CoV-2 Omicron evades our immune response and remains infective

Understanding the DNA Damage Response in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News